- Home
- AEI vs TNXP Comparison
AEI vs TNXP Comparison
Compare AEI & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEI
- TNXP
- Stock Information
- Founded
- AEI 2014
- TNXP 2007
- Country
- AEI United States
- TNXP United States
- Employees
- AEI N/A
- TNXP N/A
- Industry
- AEI Building operators
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- AEI Real Estate
- TNXP Health Care
- Exchange
- AEI Nasdaq
- TNXP Nasdaq
- Market Cap
- AEI 13.4M
- TNXP 15.1M
- IPO Year
- AEI N/A
- TNXP N/A
- Fundamental
- Price
- AEI $1.46
- TNXP $0.18
- Analyst Decision
- AEI
- TNXP Strong Buy
- Analyst Count
- AEI 0
- TNXP 2
- Target Price
- AEI N/A
- TNXP $53.50
- AVG Volume (30 Days)
- AEI 74.2K
- TNXP 29.5M
- Earning Date
- AEI 11-12-2024
- TNXP 11-07-2024
- Dividend Yield
- AEI N/A
- TNXP N/A
- EPS Growth
- AEI N/A
- TNXP N/A
- EPS
- AEI N/A
- TNXP N/A
- Revenue
- AEI $9,220,976.00
- TNXP $12,458,000.00
- Revenue This Year
- AEI N/A
- TNXP $62.53
- Revenue Next Year
- AEI N/A
- TNXP $26.17
- P/E Ratio
- AEI N/A
- TNXP N/A
- Revenue Growth
- AEI N/A
- TNXP N/A
- 52 Week Low
- AEI $0.46
- TNXP $0.12
- 52 Week High
- AEI $2.05
- TNXP $22.08
- Technical
- Relative Strength Index (RSI)
- AEI 53.17
- TNXP 50.43
- Support Level
- AEI $1.42
- TNXP $0.13
- Resistance Level
- AEI $1.67
- TNXP $0.18
- Average True Range (ATR)
- AEI 0.20
- TNXP 0.02
- MACD
- AEI -0.01
- TNXP 0.01
- Stochastic Oscillator
- AEI 41.10
- TNXP 72.00
About AEI Alset Inc. (TX)
Alset Inc is a diversified holding company engaged through its subsidiaries in the development of EHome communities and other real estate, financial services, digital transformation technologies, biohealth activities, and consumer products with operations in the United States, Singapore, Hong Kong, Australia, and South Korea. The Company operates in four business segments: real estate, digital transformation technology, Biohealth, and other business activities, and it derives a majority of its revenue from the Real Estate segment.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.